Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Autonomic Research
Published in: Clinical Autonomic Research 1/2017

Open Access 01-07-2017 | Case Vignette

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy

Authors: Brent P. Goodman, Fiona Gupta

Published in: Clinical Autonomic Research | Special Issue 1/2017

Login to get access

Excerpt

When using droxidopa, what are the criteria to adjust the dosage, combine it with other medications, and define therapeutic success? …
Literature
1.
Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A (2016) Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res 26:171–180CrossRefPubMed
2.
Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, Colosimo C, Poewe W, Pontieri FE, Wenning GK (2016) Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res 26:97–105CrossRefPubMed
3.
4.
Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R (1986) The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. BMJ 293:353–354CrossRefPubMedPubMedCentral
5.
Sandroni P, Opfer-Gehrking TL, Singer W, Low PA (2005) Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]—a follow-up survey study. Clin Auton Res 15:51–53CrossRefPubMed
6.
Smith W, Wan H, Much D, Robinson AG, Martin P (2016) Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res 26:269–277CrossRefPubMedPubMedCentral
Metadata
Title
Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
Authors
Brent P. Goodman
Fiona Gupta
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research / Issue Special Issue 1/2017
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-017-0432-8

Other articles of this Special Issue 1/2017

Clinical Autonomic Research 1/2017 Go to the issue

Case Vignette

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease

Case Vignette

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension

Case Vignette

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease

Case Vignette

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease

Case Vignette

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease

Editorial

Neurogenic orthostatic hypotension: the very basics